Developer docs
API playgroundTry for free, no card

Search company profiles

Syvento BioTech

Full company profile

uuid0037hf4

Namestring
Syvento BioTech
Legal namestring
SyVento Sp. z o.o.
Websiteurl
syvento.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

SyVento BioTech (legal entity SyVento Sp. z o.o.) is a Polish biotechnology Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in Skawina, near Kraków. The company specializes in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, serving biotech and pharmaceutical clients developing RNA-based therapeutics, gene therapies, and advanced lipid-formulated drug products. Its offerings span four integrated platforms: a Genetic Platform for end-to-end mRNA synthesis (IVT, TFF purification, oligo(dT) capture, HPLC polishing); a Delivery Platform covering liposomes, LNPs, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and SEDDS; a Manufacturing Platform scaling from 25 µl lab batches to 50 L commercial batches with 2,000–3,000 vials/hour continuous fill-and-finish; and Drug Development Expertise covering analytics, bioassay, CMC, and regulatory support.

The company operates from a state-of-the-art facility with 537 m² of sterile cGMP pharmaceutical production, 541 m² of GLP laboratory space, 646 m² of non-sterile production, and 1,478 m² of warehousing. SyVento obtained its EU GMP Certificate of Compliance on 28 April 2026 (manufacturing authorization no. 285/0662/25) and states it is the only entity in Poland offering this combined CDMO service portfolio for RNA-based therapies and LNPs with injectable manufacturing and fill-and-finish.

SyVento generates revenue through bespoke project-based CDMO contracts and long-term strategic partnerships, targeting both early-stage biotech startups and established pharmaceutical companies. Its 100% PhD-qualified R&D team, PhD-led CTO, and joint development agreement with Molecure (formerly OncoArendi, 2021) and manufacturing partnership with NanoSanguis S.A. (May 2026) anchor its commercial pipeline. Go-to-market is direct enterprise sales via a commercial advisory team and active participation in major industry conferences (BIO, TIDES USA, CDMO Live, CE BioForum, UK Biotech Day, EUROBIOTECH).

Short descriptiontext

SyVento BioTech is a Polish CDMO specializing in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, offering end-to-end mRNA synthesis, LNP formulation, GMP manufacturing, and fill-and-finish services to biotech and pharmaceutical clients developing RNA-based therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSkawina, Poland
HQ citystring
Skawina
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lipid nanoparticle CDMO, RNA synthesis services, lipid-based drug delivery, GMP contract manufacturing, pharmaceutical development services
Industry3 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical CDMO services for RNA-based therapeutics and lipid nanoparticle drug delivery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CDMO Services (Contract Development & Manufacturing)
TypeProfessional Services
Description

SyVento operates as a full-service Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early formulation development through GMP manufacturing and fill-and-finish. Revenue is generated through project-based service contracts and long-term CDMO partnerships. Services include RUO/GMP-grade mRNA synthesis, preclinical & clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing, in-house analytics, bioassay, and regulatory support.

syvento.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Syvento BioTech operates as a biotechnology Contract Development and Manufacturing Organization (CDMO) specializing in lipid-based nanocarriers and Lipid Nanoparticle (LNP) technology for RNA-based therapeutics. The company provides end-to-end services across four integrated platforms: RNA/mRNA synthesis (Genetic Platform), LNP and liposome formulation (Delivery Platform), scale-up and GMP-grade fill-and-finish manufacturing (Manufacturing Platform), and analytical/regulatory drug development support (Drug Development Expertise). Customers include biotech startups and pharmaceutical companies developing lipid-based drug products, RNA-based therapeutics, and gene therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 50L batch scale; 2000–3000 vials per hour continuous fill-and-finish
+2 more records
Product overview1 text field

Syvento BioTech is a biotechnology CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform of integrated services for lipid-based drug delivery and mRNA technology. The core offering consists of four interconnected platforms: the Genetic Platform (RNA/mRNA synthesis), the Delivery Platform (LNP and liposome formulations), the Manufacturing Platform (scale-up and fill-finish), and Drug Development Expertise (analytical and regulatory services). These platforms work together to provide end-to-end support from early development through commercialization of RNA-based therapeutics and lipid nanoparticle drug products.

Product and service5 records
1Genetic Platform (RNA Synthesis)
CategoryRNA / mRNA Synthesis Service
Description

End-to-end mRNA synthesis service covering IVT reaction, TFF purification, oligo(dT) capture, Prima S HPLC polishing for dsRNA removal, buffer exchange, and sterile filtration. Produces high-quality mRNA with high purity, flexibility, scalability, time-effectiveness, and repeatability for pre-clinical through commercial supply, for biotech startups and pharmaceutical companies developing mRNA-based drug products.

2Delivery Platform (LNP and Lipid-Based Formulation)
CategoryDrug Delivery Formulation Development
Description

Development of lipid-based drug delivery systems including liposomes, LNPs for gene therapies (DNA and RNA), Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), Nanoemulsions, and Self-Emulsifying Drug Delivery Systems (SEDDS). Modular control over particle size, surface charge, and composition; all formulations tested per QbD and ICH guidelines. Targets customers developing RNA-based therapeutics and gene therapies.

3Manufacturing Platform (Scale-up and GMP Fill-and-Finish)
CategoryGMP Manufacturing and Fill-Finish
Description

Scaling production of lipid nanocarrier formulations from laboratory scale to pilot, demo, and technical scale, including batches up to 50L. Includes GMP-grade continuous vial filling at 2,000–3,000 vials per hour (FnF), isolator technology, lyophilizers, and automated filling equipment. Supports biotech and pharmaceutical customers from lab scale through commercial readiness.

4Drug Development Expertise (Analytical, CMC, and Regulatory Support)
CategoryAnalytical and Regulatory Support Services
Description

End-to-end analytical and development services supporting drug development from early clinical phases to commercialization, including CMC process development, GMP manufacturing, bioassay, in-house analytics, and regulatory support. All formulations tested per QbD and ICH guidelines. Customers are biotech and pharmaceutical partners.

5CDMO Services (Comprehensive End-to-End Contract Development and Manufacturing)
CategoryCDMO (Contract Development and Manufacturing Organization) Services
Description

Comprehensive Contract Development and Manufacturing Organization services spanning RUO/GMP-grade mRNA synthesis, preclinical and clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing with fill-and-finish, in-house analytics, bioassay, and regulatory support. Provides end-to-end collaboration from early development through commercial readiness for biotech and pharmaceutical customers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

SyVento joined the DefenceTech Cluster / Horizon of Security initiative alongside organizations including Polish Armaments Group (PGZ), IBM Poland, ENEA, AGH University of Kraków, Kielce University of Technology, Starachowice Special Economic Zone, INFOVER, CELiUS, ELIBERTOON, and MOSTOSTAL Kielce. The initiative aims to strengthen Poland's technological resilience, strategic autonomy, and innovation capabilities through cross-sector collaboration, including in dual-use technologies, R&D, and industrial cooperation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

SyVento provides comprehensive technological and analytical support for the development and manufacturing of NanOX 4 Kidney, a next-generation kidney perfusion fluid based on a synthetic oxygen carrier, as a Class III medical device. SyVento delivers technical support of the manufacturing process, including analytics and production of preclinical and clinical batches.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

SyVento and OncoArendi (now Molecure) signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. This collaboration solidified SyVento's reputation in the field of lipid-based drug delivery and RNA therapeutics.

Strategic tierMinorTypeOthers
Description

Listed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.

5AMM (Alliance for Modern Medicine / mrnamedicines.org)
Strategic tierMinorTypeOthers
Description

Listed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.

syvento.com
Strategic tierMinorTypeOthers
Description

Listed as a partner on SyVento's About Us page. BioinMed is a biotech/medtech industry association. Nature of collaboration not detailed in available source material.

7CE BioForum
Strategic tierMinorTypeOthers
Description

Listed as a partner on SyVento's About Us page. CE BioForum is a Central European biotech industry platform. Nature of collaboration not detailed in available source material.

syvento.com
Strategic tierMinorTypeOthers
Description

Listed as a partner on SyVento's About Us page. LifeScience Cluster connects biotech, pharma, and academic organizations in Poland. Nature of collaboration not detailed in available source material.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration partner listed on SyVento's About Us page. SyVento pursues academic partnerships for joint research projects on LNP and lipid-based drug delivery, knowledge sharing, access to specialized expertise, grant and funding opportunities, student internships and training, and joint publications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration partner listed on SyVento's About Us page. Dominik Lipka, CTO, earned his PhD at the University of Wrocław's Faculty of Biotechnology, Department of Lipids and Liposomes. SyVento engages in joint research, student internships, and publications with academic institutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs with dedicated mRNA and lipid nanoparticle capabilities at scale, serving both clinical and commercial supply. It represents the global incumbent against which SyVento will compete for biotech outsourcing contracts.

TypeEmerging player
Description

Acuitas is a Canadian specialist in ionizable cationic lipid and LNP technology for RNA therapeutics (used in Moderna's and Pfizer-BioNTech's COVID vaccines). It is directly comparable to SyVento's Delivery Platform for LNP formulation know-how.

TypeEmerging player
Description

CureVac is a clinical-stage mRNA company with in-house manufacturing capabilities and external CDMO partnerships. It is comparable as a European mRNA/LNP operator, though it remains primarily a therapeutics developer rather than a pure CDMO.

TypeBroad incumbent
Description

Rentschler is a German-based CDMO focused on complex biologics including mAb, recombinant protein, and increasingly nucleic-acid-based therapeutics. It is a relevant European regional incumbent with overlapping customer base and GMP capabilities.

TypeBroad incumbent
Description

Evonik is a leading supplier of functional excipients and lipids for LNP formulations (including for COVID-19 vaccines) and offers CDMO services for parenteral drug products and complex formulations. It is a broad incumbent in the LNP-lipid value chain SyVento serves.

TypeDirect peer
Description

Aldevron is a US-based CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapies. Its nucleic-acid CDMO offering directly overlaps with SyVento's Genetic Platform and GMP mRNA synthesis service.

7BioNTech IMFS (formerly Polymun Scientific)
TypeDirect peer
Description

BioNTech IMFS is the contract manufacturing arm of BioNTech, offering mRNA/LNP CDMO services including GMP-grade mRNA production and LNP encapsulation from a German facility. It is the closest direct competitor to SyVento in Europe for end-to-end mRNA-LNP CDMO work.

TypeBroad incumbent
Description

Catalent is a major global CDMO with extensive fill-finish, biologics, and nucleic-acid capabilities, including an mRNA-focused partnership with Moderna. Its breadth and scale make it the broad incumbent reference for SyVento's service portfolio.

TypeBroad incumbent
Description

AGC Biologics is a global CDMO with cell, gene therapy, and biologics GMP manufacturing including microbial and mammalian platforms. Its integrated CDMO model parallels SyVento's positioning as an end-to-end CDMO partner.

TypeEmerging player
Description

Genevant develops lipid nanoparticle delivery technology for RNA therapeutics (siRNA, mRNA, gene editing) and licenses its platform plus offers formulation services. Its LNP-centric model overlaps with SyVento's Delivery Platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Syvento BioTech

Biopharmaceutical CDMO services for RNA-based therapeutics and lipid nanoparticle drug deliverysyvento.com

SyVento BioTech is a Polish CDMO specializing in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, offering end-to-end mRNA synthesis, LNP formulation, GMP manufacturing, and fill-and-finish services to biotech and pharmaceutical clients developing RNA-based therapeutics.

What Syvento BioTech does

SyVento BioTech (legal entity SyVento Sp. z o.o.) is a Polish biotechnology Contract Development and Manufacturing Organization (CDMO) founded in 2015 and headquartered in Skawina, near Kraków. The company specializes in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, serving biotech and pharmaceutical clients developing RNA-based therapeutics, gene therapies, and advanced lipid-formulated drug products. Its offerings span four integrated platforms: a Genetic Platform for end-to-end mRNA synthesis (IVT, TFF purification, oligo(dT) capture, HPLC polishing); a Delivery Platform covering liposomes, LNPs, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and SEDDS; a Manufacturing Platform scaling from 25 µl lab batches to 50 L commercial batches with 2,000–3,000 vials/hour continuous fill-and-finish; and Drug Development Expertise covering analytics, bioassay, CMC, and regulatory support.

The company operates from a state-of-the-art facility with 537 m² of sterile cGMP pharmaceutical production, 541 m² of GLP laboratory space, 646 m² of non-sterile production, and 1,478 m² of warehousing. SyVento obtained its EU GMP Certificate of Compliance on 28 April 2026 (manufacturing authorization no. 285/0662/25) and states it is the only entity in Poland offering this combined CDMO service portfolio for RNA-based therapies and LNPs with injectable manufacturing and fill-and-finish.

SyVento generates revenue through bespoke project-based CDMO contracts and long-term strategic partnerships, targeting both early-stage biotech startups and established pharmaceutical companies. Its 100% PhD-qualified R&D team, PhD-led CTO, and joint development agreement with Molecure (formerly OncoArendi, 2021) and manufacturing partnership with NanoSanguis S.A. (May 2026) anchor its commercial pipeline. Go-to-market is direct enterprise sales via a commercial advisory team and active participation in major industry conferences (BIO, TIDES USA, CDMO Live, CE BioForum, UK Biotech Day, EUROBIOTECH).

Syvento BioTech firmographics

Firmographics
Name
Syvento BioTech
Legal name
SyVento Sp. z o.o.
Website
https://syvento.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
SyVento BioTech is a Polish CDMO specializing in lipid-based nanocarriers and lipid nanoparticle (LNP) technology, offering end-to-end mRNA synthesis, LNP formulation, GMP manufacturing, and fill-and-finish services to biotech and pharmaceutical clients developing RNA-based therapeutics.
Ownership category
akta.pro rank

Syvento BioTech industry classification

Industry
Product category
Biopharmaceutical CDMO services for RNA-based therapeutics and lipid nanoparticle drug delivery
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Lipid nanoparticle CDMO
  • RNA synthesis services
  • Lipid-based drug delivery
  • GMP contract manufacturing
  • Pharmaceutical development services

Where Syvento BioTech is headquartered

Location

Headquarters

HQ city
Skawina
HQ country
Poland
HQ region
Europe

Offices2 records

Markets served

Syvento BioTech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain

Revenue model

  1. CDMO Services (Contract Development & Manufacturing): SyVento operates as a full-service Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early formulation development through GMP manufacturing and fill-and-finish. Revenue is generated through project-based service contracts and long-term CDMO partnerships. Services include RUO/GMP-grade mRNA synthesis, preclinical & clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing, in-house analytics, bioassay, and regulatory support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Syvento BioTech product offering

Product offering

Core offering

Syvento BioTech operates as a biotechnology Contract Development and Manufacturing Organization (CDMO) specializing in lipid-based nanocarriers and Lipid Nanoparticle (LNP) technology for RNA-based therapeutics. The company provides end-to-end services across four integrated platforms: RNA/mRNA synthesis (Genetic Platform), LNP and liposome formulation (Delivery Platform), scale-up and GMP-grade fill-and-finish manufacturing (Manufacturing Platform), and analytical/regulatory drug development support (Drug Development Expertise). Customers include biotech startups and pharmaceutical companies developing lipid-based drug products, RNA-based therapeutics, and gene therapies.

Product overview

Syvento BioTech is a biotechnology CDMO (Contract Development and Manufacturing Organization) offering a comprehensive platform of integrated services for lipid-based drug delivery and mRNA technology. The core offering consists of four interconnected platforms: the Genetic Platform (RNA/mRNA synthesis), the Delivery Platform (LNP and liposome formulations), the Manufacturing Platform (scale-up and fill-finish), and Drug Development Expertise (analytical and regulatory services). These platforms work together to provide end-to-end support from early development through commercialization of RNA-based therapeutics and lipid nanoparticle drug products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genetic Platform (RNA Synthesis) End-to-end mRNA synthesis service covering IVT reaction, TFF purification, oligo(dT) capture, Prima S HPLC polishing for dsRNA removal, buffer exchange, and sterile filtration. Produces high-quality mRNA with high purity, flexibility, scalability, time-effectiveness, and repeatability for pre-clinical through commercial supply, for biotech startups and pharmaceutical companies developing mRNA-based drug products.
  • Delivery Platform (LNP and Lipid-Based Formulation) Development of lipid-based drug delivery systems including liposomes, LNPs for gene therapies (DNA and RNA), Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), Nanoemulsions, and Self-Emulsifying Drug Delivery Systems (SEDDS). Modular control over particle size, surface charge, and composition; all formulations tested per QbD and ICH guidelines. Targets customers developing RNA-based therapeutics and gene therapies.
  • Manufacturing Platform (Scale-up and GMP Fill-and-Finish) Scaling production of lipid nanocarrier formulations from laboratory scale to pilot, demo, and technical scale, including batches up to 50L. Includes GMP-grade continuous vial filling at 2,000–3,000 vials per hour (FnF), isolator technology, lyophilizers, and automated filling equipment. Supports biotech and pharmaceutical customers from lab scale through commercial readiness.
  • Drug Development Expertise (Analytical, CMC, and Regulatory Support) End-to-end analytical and development services supporting drug development from early clinical phases to commercialization, including CMC process development, GMP manufacturing, bioassay, in-house analytics, and regulatory support. All formulations tested per QbD and ICH guidelines. Customers are biotech and pharmaceutical partners.
  • CDMO Services (Comprehensive End-to-End Contract Development and Manufacturing) Comprehensive Contract Development and Manufacturing Organization services spanning RUO/GMP-grade mRNA synthesis, preclinical and clinical drug development, process optimization, scale-up and technology transfer, GMP manufacturing with fill-and-finish, in-house analytics, bioassay, and regulatory support. Provides end-to-end collaboration from early development through commercial readiness for biotech and pharmaceutical customers.

Quantifiable outcome

  • Up to 50L batch scale; 2000–3000 vials per hour continuous fill-and-finish
  • +2 more outcomes

Companies that use Syvento BioTech

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Syvento BioTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Syvento BioTech partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor and core.

  • DefenceTech Cluster / Horizon of Security (Horyzont Bezpieczeństwa)minorStrategic or Co-development Partner · 1 June 2026SyVento joined the DefenceTech Cluster / Horizon of Security initiative alongside organizations including Polish Armaments Group (PGZ), IBM Poland, ENEA, AGH University of Kraków, Kielce University of Technology, Starachowice Special Economic Zone, INFOVER, CELiUS, ELIBERTOON, and MOSTOSTAL Kielce. The initiative aims to strengthen Poland's technological resilience, strategic autonomy, and innovation capabilities through cross-sector collaboration, including in dual-use technologies, R&D, and industrial cooperation.
  • NanoSanguis S.A.coreStrategic or Co-development Partner · 1 May 2026SyVento provides comprehensive technological and analytical support for the development and manufacturing of NanOX 4 Kidney, a next-generation kidney perfusion fluid based on a synthetic oxygen carrier, as a Class III medical device. SyVento delivers technical support of the manufacturing process, including analytics and production of preclinical and clinical batches.
  • Molecure (formerly OncoArendi)coreStrategic or Co-development Partner · 1 January 2021SyVento and OncoArendi (now Molecure) signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02. This collaboration solidified SyVento's reputation in the field of lipid-based drug delivery and RNA therapeutics.
  • KymosminorOthersListed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.
  • AMM (Alliance for Modern Medicine / mrnamedicines.org)minorOthersListed as a partner on SyVento's About Us page. Nature of collaboration not detailed in available source material.
  • BioinMedminorOthersListed as a partner on SyVento's About Us page. BioinMed is a biotech/medtech industry association. Nature of collaboration not detailed in available source material.
  • CE BioForumminorOthersListed as a partner on SyVento's About Us page. CE BioForum is a Central European biotech industry platform. Nature of collaboration not detailed in available source material.
  • LifeScience Cluster (KlasterLifeScience.pl)minorOthersListed as a partner on SyVento's About Us page. LifeScience Cluster connects biotech, pharma, and academic organizations in Poland. Nature of collaboration not detailed in available source material.
  • Jagiellonian University (UJ)coreStrategic or Co-development PartnerAcademic collaboration partner listed on SyVento's About Us page. SyVento pursues academic partnerships for joint research projects on LNP and lipid-based drug delivery, knowledge sharing, access to specialized expertise, grant and funding opportunities, student internships and training, and joint publications.
  • University of Wrocław (UWR)coreStrategic or Co-development PartnerAcademic collaboration partner listed on SyVento's About Us page. Dominik Lipka, CTO, earned his PhD at the University of Wrocław's Faculty of Biotechnology, Department of Lipids and Liposomes. SyVento engages in joint research, student internships, and publications with academic institutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Syvento BioTech competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Lonza is one of the world's largest CDMOs with dedicated mRNA and lipid nanoparticle capabilities at scale, serving both clinical and commercial supply. It represents the global incumbent against which SyVento will compete for biotech outsourcing contracts.
  • Rentschler Biopharma: Rentschler is a German-based CDMO focused on complex biologics including mAb, recombinant protein, and increasingly nucleic-acid-based therapeutics. It is a relevant European regional incumbent with overlapping customer base and GMP capabilities.
  • Evonik Health Care: Evonik is a leading supplier of functional excipients and lipids for LNP formulations (including for COVID-19 vaccines) and offers CDMO services for parenteral drug products and complex formulations. It is a broad incumbent in the LNP-lipid value chain SyVento serves.
  • Catalent (Novo Holdings): Catalent is a major global CDMO with extensive fill-finish, biologics, and nucleic-acid capabilities, including an mRNA-focused partnership with Moderna. Its breadth and scale make it the broad incumbent reference for SyVento's service portfolio.
  • AGC Biologics: AGC Biologics is a global CDMO with cell, gene therapy, and biologics GMP manufacturing including microbial and mammalian platforms. Its integrated CDMO model parallels SyVento's positioning as an end-to-end CDMO partner.

Emerging players

  • Acuitas Therapeutics: Acuitas is a Canadian specialist in ionizable cationic lipid and LNP technology for RNA therapeutics (used in Moderna's and Pfizer-BioNTech's COVID vaccines). It is directly comparable to SyVento's Delivery Platform for LNP formulation know-how.
  • CureVac: CureVac is a clinical-stage mRNA company with in-house manufacturing capabilities and external CDMO partnerships. It is comparable as a European mRNA/LNP operator, though it remains primarily a therapeutics developer rather than a pure CDMO.
  • Genevant Sciences: Genevant develops lipid nanoparticle delivery technology for RNA therapeutics (siRNA, mRNA, gene editing) and licenses its platform plus offers formulation services. Its LNP-centric model overlaps with SyVento's Delivery Platform.

Direct peers

  • Aldevron (Danaher): Aldevron is a US-based CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for cell and gene therapies. Its nucleic-acid CDMO offering directly overlaps with SyVento's Genetic Platform and GMP mRNA synthesis service.
  • BioNTech IMFS (formerly Polymun Scientific): BioNTech IMFS is the contract manufacturing arm of BioNTech, offering mRNA/LNP CDMO services including GMP-grade mRNA production and LNP encapsulation from a German facility. It is the closest direct competitor to SyVento in Europe for end-to-end mRNA-LNP CDMO work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Syvento BioTech social profiles

Digital presence

Syvento BioTech compliance and trust

Trust signal

Compliance3 records

Syvento BioTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Syvento BioTech leadership team

Management profile

Number of profiles

Profiles7 records

Syvento BioTech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Syvento BioTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syvento BioTech

What does Syvento BioTech do?

Syvento BioTech operates as a biotechnology Contract Development and Manufacturing Organization (CDMO) specializing in lipid-based nanocarriers and Lipid Nanoparticle (LNP) technology for RNA-based therapeutics. The company provides end-to-end services across four integrated platforms: RNA/mRNA synthesis (Genetic Platform), LNP and liposome formulation (Delivery Platform), scale-up and GMP-grade fill-and-finish manufacturing (Manufacturing Platform), and analytical/regulatory drug development support (Drug Development Expertise). Customers include biotech startups and pharmaceutical companies developing lipid-based drug products, RNA-based therapeutics, and gene therapies.

Is Syvento BioTech a public or private company?

Syvento BioTech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Syvento BioTech founded?

Syvento BioTech was founded in 2015. It employs 11 to 50 people.

Where is Syvento BioTech based?

Syvento BioTech is headquartered in Skawina, Poland, in the Europe region.

How does Syvento BioTech make money?

One revenue line is on record: CDMO Services (Contract Development & Manufacturing).

Who are Syvento BioTech's main competitors?

Broad incumbents on record are Lonza, Rentschler Biopharma, Evonik Health Care, Catalent (Novo Holdings) and AGC Biologics. Emerging players are Acuitas Therapeutics, CureVac and Genevant Sciences. Direct peers are Aldevron (Danaher) and BioNTech IMFS (formerly Polymun Scientific).

Does Syvento BioTech have an API?

No public API is recorded for Syvento BioTech.

What industry is Syvento BioTech in?

Syvento BioTech's product category is Biopharmaceutical CDMO services for RNA-based therapeutics and lipid nanoparticle drug delivery. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales